Who makes ISIS 443139 10 mg?

ISIS 443139 10 mg is developed by Ionis Pharmaceuticals, Inc..

What development phase is ISIS 443139 10 mg in?

ISIS 443139 10 mg is in Phase 1.

What are the side effects of ISIS 443139 10 mg?

Common side effects include Procedural pain, Headache, Post lumbar puncture syndrome, Fall, Contusion, Nasopharyngitis.

Last reviewed 2026-04-20 · How we verify

ISIS 443139 10 mg

Ionis Pharmaceuticals, Inc. · Phase 1 active Small molecule Quality 20/100

At a glance

Generic name	ISIS 443139 10 mg
Also known as	IONIS HTTRx
Sponsor	Ionis Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Procedural pain
Headache
Post lumbar puncture syndrome
Fall
Contusion
Nasopharyngitis
Rhinitis
Arthralgia
Skin abrasion
Joint injury
Laceration
Tooth injury

Key clinical trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ISIS 443139 10 mg CI brief — competitive landscape report
ISIS 443139 10 mg updates RSS · CI watch RSS
Ionis Pharmaceuticals, Inc. portfolio CI